-

ROME Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

BOSTON--(BUSINESS WIRE)--ROME Therapeutics, a biotechnology company harnessing the power of the dark genome to develop breakthrough medicines for serious diseases, today announced that Rosana Kapeller, M.D., Ph.D., President, CEO and Co-founder of ROME, and other members of the ROME Senior Leadership Team will participate in the TD Cowen 44th Annual Health Care Conference on Wednesday, March 6, 2024, in Boston, Massachusetts.

About ROME
ROME Therapeutics is developing novel therapies for a range of serious diseases, including autoimmune disease, cancer, and neurodegeneration, by illuminating the role of the dark genome — the vast genomic expanse beyond the traditional genes, which includes virus-like repetitive elements and non-coding sequences — in human health and disease. Leveraging the company’s unprecedented data sciences platform, ROME has built a deep pipeline of therapies targeting the dark genome. To lead this exploration, ROME has assembled a team of world-class leaders in drug discovery and development across immunology, oncology, chemistry, and machine learning. ROME is based in Boston, Mass. For more information, please visit www.rometx.com.

Contacts

Investor
Monique Allaire
THRUST Strategic Communications
monique@thrustsc.com

Media
Lisa Raffensperger
Ten Bridge Communications
lisa@tenbridgecommunications.com

ROME Therapeutics


Release Summary
ROME Therapeutics today announced that members of the ROME Senior Leadership Team will participate in the TD Cowen 44th Annual Health Care Conference.
Release Versions

Contacts

Investor
Monique Allaire
THRUST Strategic Communications
monique@thrustsc.com

Media
Lisa Raffensperger
Ten Bridge Communications
lisa@tenbridgecommunications.com

More News From ROME Therapeutics

ROME Therapeutics Appoints Heike Keilhack, Ph.D., as Chief Scientific Officer

BOSTON--(BUSINESS WIRE)--ROME Therapeutics today announced the appointment of cancer biology and immunology expert Heike Keilhack, Ph.D., as Chief Scientific Officer....

ROME Publishes Landmark Nature Paper Revealing First High-Resolution Structure of LINE-1 Reverse Transcriptase (RT) for Drug Discovery

BOSTON--(BUSINESS WIRE)--ROME Therapeutics today announced a landmark publication in Nature revealing the first high-resolution structure of the LINE-1 reverse transcriptase....

ROME Therapeutics Presents First Data to Validate LINE-1 RT as a Novel Target in Autoimmune Diseases and the Therapeutic Potential of its First-in-Class LINE-1 RT Inhibitors

BOSTON--(BUSINESS WIRE)--ROME Therapeutics announced new data validating the reverse transcriptase (RT) of LINE-1 as a novel target for drug discovery in autoimmune diseases....
Back to Newsroom